Investors
FAQ
What is AXIM Biotechnologies, Inc.'s stock symbol?
Our stock is traded on the OTCQB under the symbol AXIM.
How can I buy AXIM shares?
You can buy AXIM shares through a broker, just as you would other securities.
How can I keep up to date with latest developments at AXIM?
You can register to receive updates announced by AXIM by submitting your email address in Email Alerts on the Investor Relations section of our website.
When was AXIM Biotechnologies, Inc. incorporated?
2010
When did AXIM Biotechnologies, Inc. become a public company?
March 2014
Where is AXIM Biotechnologies, Inc. located?
6191 Cornerstone Court, E., Suite 114,
San Diego, CA 92121
When is AXIM Biotechnologies, Inc.'s fiscal year end?
December 31st
Who is AXIM Biotechnologies, Inc.'s transfer agent?
Action Stock Transfer Corporation
2469 E. Fort Union Blvd
Suite 214
Salt Lake City, UT 84121
T: 801-274-1088
info@actionstocktransfer.com
www.actionstocktransfer.com
Who is AXIM Biotechnologies, Inc.'s independent auditor?
RBSM LLP
805 Third Avenue
Suite 902
New York, NY 10022
T: 212-868-3669
www.rbsmllp.com
Who is AXIM Biotechnologies, Inc.'s outside legal counsel?
Phillip E. Koehnke, APC
PO Box 235472
Encinitas, CA 92024
T: 858-229-8116
pek@peklaw.com
Email Alerts
Stay informed and receive company updates straight to your inbox
Recent News
AXIM® Biotechnologies Files Patent on Fentanyl Neutralizing Antibody Test, Applies for DEA License to Work With Controlled Substance
Diagnostic Healthcare Solutions Company Developing New Test Designed to Measure Neutralizing Antibodies of Deadly Opioid Fentanyl SAN DIEGO, TBD DATE, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an...
AXIM Biotechnologies CEO Issues Letter to Shareholders
Summary: In 2022, AXIM® finalized optimization of its R&D and manufacturing infrastructure to be used in its diagnostic program AXIM will continue to generate revenue from its two FDA-cleared dry eye disease (DED) diagnostic tests through commercialization partner...
AXIM® Biotechnologies Develops Novel Dual IgE/MMP-9 Rapid Ophthalmological Diagnostic Test; Files Provisional Patent
SAN DIEGO, Dec. 13, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today that it has filed a provision patent application with...
